Rationally designed dendritic silica nanoparticles for oral delivery of exenatide
Type 2 diabetes makes up approximately 85% of all diabetic cases and it is linked to approximately one-third of all hospitalisations. Newer therapies with long-acting biologics such as glucagon-like peptide-1 (GLP-1) analogues have been promising in managing the disease, but they cannot reverse the...
Main Author: | |
---|---|
Other Authors: | , , , , , , , , , |
Format: | article |
Language: | eng |
Published: |
2019
|
Subjects: | |
Online Access: | https://hdl.handle.net/10216/137931 |
Country: | Portugal |
Oai: | oai:repositorio-aberto.up.pt:10216/137931 |